Drug Discovery World
JULY 31, 2023
Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops. “On
pharmaphorum
NOVEMBER 17, 2021
The Future of Drug Delivery and Combination Product Device Design. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 9, 2023
Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”
The Pharma Data
OCTOBER 27, 2020
3a will continue to advance its industrial design, product usability, labelling compliance, regulatory approval, and production planning work in parallel to its validation studies. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
The Pharma Data
DECEMBER 20, 2020
With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.
The Pharma Data
DECEMBER 28, 2020
is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About BetterLife Pharma Inc. BetterLife Pharma Inc.
The Pharma Data
JANUARY 18, 2021
Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV).
Expert insights. Personalized for you.
52 
Let's personalize your content